BioPorto granted Werfen Group's Instrumentation Laboratory subsidiary a non-exclusive license to its patent portfolio covering lipocalin (LCN2; NGAL), a biomarker used for diagnosing acute kidney injury

BioPorto Diagnostics A/S

Denmark / Medical Devices and Diagnostics

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Werfen Group S.A.

Spain / Tools, Services, and Manufacturing

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced